Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11098325 | 0.94 | LMNA (0.40) | TNKS2IMPDH2IMPDH1LMNAPGR | |
| SCHEMBL24784363 | 0.92 | LMNA (0.42) | IMPDH2IMPDH1LMNAPGRCYP3A4 | |
| SCHEMBL24783641 | 0.92 | LMNA (0.42) | IMPDH2IMPDH1LMNAPGRCYP3A4 | |
| SCHEMBL8570251 | 0.89 | IMPDH2 (0.41) | IMPDH2IMPDH1CA2CA4 | |
| SCHEMBL8564172 | 0.87 | IMPDH2 (0.41) | TNKS2IMPDH2IMPDH1LMNAPGR | |
| SCHEMBL11173917 | 0.84 | LMNA (0.34) | IMPDH1LMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL14896505 | 0.83 | TSHR (0.41) | IMPDH2IMPDH1MAPTMAPK1HTT | |
| SCHEMBL14894762 | 0.82 | LMNA (0.33) | LMNAPGRCYP3A4CYP2D6MAPT | |
| SCHEMBL1784681 | 0.81 | IMPDH1 (0.40) | TNKS2IMPDH2IMPDH1LMNAPGR | |
| SCHEMBL19463178 | 0.81 | TNKS2 (0.42) | TNKS2IMPDH2IMPDH1LMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911656-B1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX SA (FR) | 2020-12-02 | — | — | EP | disclosed |
| CN-104994845-B | Quinonyl Nitric oxidedonating compounds for ophthalmic applications | 尼科斯科学爱尔兰公司 | 2017-11-17 | — | — | CN | disclosed |
| US-20170246195-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS INC (NZ) | 2017-08-31 | — | — | US | disclosed |
| CN-103687843-B | Quinone based nitric oxide donor compounds | 尼科斯科学爱尔兰公司 | 2016-11-16 | — | — | CN | disclosed |
| US-9446015-B2 | Quinone based nitric oxide donating compounds for ophthalmic use | NICOX SCIENCE IRELAND (IE) | 2016-09-20 | — | — | US | disclosed |
| CN-103739499-B | Quinonyl Nitric oxidedonating compounds | 尼科斯科学爱尔兰公司 | 2016-09-07 | — | — | CN | disclosed |
| CN-104994845-A | Quinone based nitric oxide donating compounds for ophthalmic use | NICOX SA | 2015-10-21 | — | — | CN | disclosed |
| WO-2015155234-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155234-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2015-10-15 | — | — | WO | disclosed |
| US-20150283106-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX SA (FR) | 2015-10-08 | — | — | US | disclosed |
| US-7888334-B2 | lipophilic cationic moiety linked by to an antioxidant; a salt forming anion; does not exhibit reactivity against the lipophilic cationic moiety; Parkinson's, Alzheimer's disease, Huntington's Chorea and Friedreich's Ataxia | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888334-B2 | lipophilic cationic moiety linked by to an antioxidant; a salt forming anion; does not exhibit reactivity against the lipophilic cationic moiety; Parkinson's, Alzheimer's disease, Huntington's Chorea and Friedreich's Ataxia | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080161267-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070238709-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238709-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238709-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20060229278-A1 | Mitoquinone derivatives used as mitochondrially targeted antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1664069-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | Antipodean Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005019232-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019233-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229278-A1 | Mitoquinone derivatives used as mitochondrially targeted antioxidants | COQ8A, MFN2, SQOR | TNKS2 1340/4885IMPDH2 2348/4885IMPDH1 2732/4885 |
| US-20080161267-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | PRDX5, MT-ND2, TXN2 | TNKS2 986/4885IMPDH2 1971/4885IMPDH1 2181/4885 |
| US-20070238709-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | PRDX5, TXNRD2, TXN2 | TNKS2 1124/4885IMPDH2 1860/4885IMPDH1 2009/4885 |
| US-20170246195-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | PRDX5, TXN2, MT-ND2 | TNKS2 975/4885IMPDH2 2157/4885IMPDH1 2361/4885 |
| US-20150283106-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NOS1, NOS3, NOS2 | TNKS2 2255/4885IMPDH2 414/4885IMPDH1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.